Meningococcal disease
Erin Passmore A , Robert Booy B and Mark Ferson C
+ Author Affiliations
- Author Affiliations
A NSW Public Health Officer Training Program, NSW Ministry of Health
B National Centre for Immunisation Research and Surveillance
C South East Sydney Illawarra Public Health Unit
NSW Public Health Bulletin 23(2) 36-36 https://doi.org/10.1071/NB11052
Published: 28 March 2012
References
[1] Chiu C, Dey A, Wang H, Menzies R, Deeks S, Mahajan D, et al. Meningococcal Disease. In: Vaccine Preventable Diseases in Australia, 2005 to 2007. Commun Dis Intell 2010; 34 S1–167.[2] Novartis. Novartis submits Bexsero®, a multi-component meningococcal B vaccine, for regulatory review in Europe. Available at: http://www.novartis.com/newsroom/media-releases/en/2010/1475256.shtml (Cited 15 December 2011).
[3] NSW Health Department Notifiable Conditions Information Management System (NCIMS). Communicable Diseases Branch and Centre for Epidemiology and Research, NSW Ministry of Health.
[4] Patel MS. Australia’s century of meningococcal disease: development and the changing ecology of an accidental pathogen. Med J Aust 2007; 186 136–41.
[5] Borg J, Christie D, Coen PG, Booy R, Viner R. Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study. Pediatrics 2009; 123 e502–9.
| Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study.Crossref | GoogleScholarGoogle Scholar |
